NFKB1 and cancer: In particular, endothelial–mesenchymal transition has been proposed to occur after anthracycline treatment and to initiate vascular remodeling [133]; anthracyclines are known triggers of NFκB activation [134] and specifically initiate endothelial-to-mesenchymal transition [135] on the one hand, and on the other hand, NFκB activation protects cancer cells from apoptosis [136].